To avoid cell specific effects, another BCR-ABL positive cell line, KU812 and BCR-ABL positive CML patient cells, AD155, were used to determine Gleevec effect on TA. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.